In conclusion, we have developed 64Cu-DOTA-anti-CTLA-4 mAb and evaluated its potential as a new radiotracer for the noninvasive evaluation of CTLA-4 expression in tumor. This evidence concerns the gene CTLA4 and neoplasm.